These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36195630)

  • 1. Effects of systemic anticoagulation in a murine model of compensatory lung growth.
    Yu LJ; Ko VH; Tsikis ST; Dao DT; Secor JD; Pan A; Cho BS; Michell PD; Fligor SC; Kishikawa H; Puder M
    Pediatr Res; 2023 Jun; 93(7):1846-1855. PubMed ID: 36195630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct thrombin inhibitors fail to reverse the negative effects of heparin on lung growth and function after murine left pneumonectomy.
    Tsikis ST; Hirsch TI; Klouda T; Fligor SC; Pan A; Joiner MM; Wang SZ; Quigley M; Devietro A; Mitchell PD; Kishikawa H; Yuan K; Puder M
    Am J Physiol Lung Cell Mol Physiol; 2024 Mar; 326(3):L213-L225. PubMed ID: 38113296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct thrombin inhibitors as alternatives to heparin to preserve lung growth and function in a murine model of compensatory lung growth.
    Tsikis ST; Hirsch TI; Fligor SC; Pan A; Joiner MM; Devietro A; Mitchell PD; Kishikawa H; Gura KM; Puder M
    Sci Rep; 2022 Dec; 12(1):21117. PubMed ID: 36477689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the mechanisms of VEGF-mediated compensatory lung growth: the role of the VEGF heparin-binding domain.
    Yu LJ; Ko VH; Dao DT; Secor JD; Pan A; Cho BS; Mitchell PD; Kishikawa H; Bielenberg DR; Puder M
    Sci Rep; 2021 Jun; 11(1):11827. PubMed ID: 34088930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin impairs angiogenic signaling and compensatory lung growth after left pneumonectomy.
    Dao DT; Anez-Bustillos L; Ourieff J; Pan A; Mitchell PD; Kishikawa H; Fell GL; Baker MA; Watnick RS; Chen H; Hamilton TE; Rogers MS; Bielenberg DR; Puder M
    Angiogenesis; 2018 Nov; 21(4):837-848. PubMed ID: 29956017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low molecular weight heparin and unfractionated heparin are both effective at accelerating pulmonary vascular maturation in neonatal rabbits.
    O'Blenes SB; Merklinger SL; Jegatheeswaran A; Campbell A; Rabinovitch M; Rebeyka I; Van Arsdell G
    Circulation; 2003 Sep; 108 Suppl 1():II161-6. PubMed ID: 12970226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
    Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI
    Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct effects of unfractionated heparin versus bivalirudin on circulating angiogenic peptides.
    Kapur NK; Shenoy C; Yunis AA; Mohammad NN; Wilson S; Paruchuri V; Mackey EE; Qiao X; Shah A; Esposito ML; Karas RH; Jaffe IZ
    PLoS One; 2012; 7(4):e34344. PubMed ID: 22509290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deficiency in pigment epithelium-derived factor accelerates pulmonary growth and development in a compensatory lung growth model.
    Ko VH; Yu LJ; Secor JD; Pan A; Mitchell PD; Kishikawa H; Puder M
    FASEB J; 2021 Oct; 35(10):e21850. PubMed ID: 34569654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.
    Chan AK; Berry LR; Monagle PT; Andrew M
    Thromb Haemost; 2002 Apr; 87(4):606-13. PubMed ID: 12008942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low molecular weight heparin for prevention of microvascular occlusion in digital replantation.
    Lin PT; Wang SH; Chi CC
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD009894. PubMed ID: 32302004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low molecular weight heparin for prevention of microvascular occlusion in digital replantation.
    Chen YC; Chi CC; Chan FC; Wen YW
    Cochrane Database Syst Rev; 2013 Jul; (7):CD009894. PubMed ID: 23836382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.
    Junqueira DR; Zorzela LM; Perini E
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007557. PubMed ID: 28431186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight heparin for prevention of central venous catheter-related thrombosis in children.
    Pelland-Marcotte MC; Amiri N; Avila ML; Brandão LR
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD005982. PubMed ID: 32557627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism.
    Robertson L; Jones LE
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD001100. PubMed ID: 28182249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin.
    Marchetti M; Vignoli A; Russo L; Balducci D; Pagnoncelli M; Barbui T; Falanga A
    Thromb Res; 2008; 121(5):637-45. PubMed ID: 17692905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients.
    Junqueira DR; Perini E; Penholati RR; Carvalho MG
    Cochrane Database Syst Rev; 2012 Sep; (9):CD007557. PubMed ID: 22972111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance.
    Li Y; Rodriquez M; Spencer FA; Becker RC
    J Thromb Thrombolysis; 2002 Oct; 14(2):123-9. PubMed ID: 12714831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
    Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
    Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.